Logo image
Sign in
Back
Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study
Journal article   Peer reviewed

Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study

François Ghiringhelli, Julie Vincent, Leila Bengrine, Christophe Borg, Jean Louis Jouve, Romaric Loffroy, Boris Guiu, Julie Blanc and Aurélie Bertaut
Journal of Cancer Research and Clinical Oncology, Vol.145(9), pp.2357-2363
09/2019
DOI: https://doi.org/10.1007/s00432-019-02970-8

Abstract

Colorectal cancer Hepatic arterial infusion Liver metastasis Oxaliplatin Raltitrexed
Background: Hepatic arterial infusion (HAI) of chemotherapy could be used in patients with liver-only metastatic colorectal cancer (mCRC) to fight against chemoresistance. We previously reported the efficacy of raltitrexed plus oxaliplatin (HAI) in a retrospective series. We performed a randomized two-stage phase-II study to evaluate the efficacy of HAI of the combination of raltitrexed and oxaliplatin in refractory mCRC with only liver metastases in comparison with standard of care.
url
Find in HALView

Metrics

1 Record Views

Details

Logo image